‍Boston, MA – January 27, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.

This publication describes an optimization of the scale up process of CVN424 to multi-kilogram scale. The development efforts delivered a safe and robust synthesis, which occurred in five linear steps and is now being used for further production of larger quantities of CVN424.

The publication can be reviewed here: https://pubs.acs.org/doi/abs/10.1021/acs.oprd.2c00181

About Cerevance

Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit www.cerevance.com.

Contacts 

Cerevance: 

Johnna Simoes, ir@cerevance.com

Media

Andrew Mielach, amielach@lifescicomms.com, +1- 646-876-5868